Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nautilus Biotechnology Inc NAUT

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform... see more

Recent & Breaking News (NDAQ:NAUT)

Nautilus Biotechnology Appoints Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development

GlobeNewswire August 1, 2022

Nautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022

GlobeNewswire July 13, 2022

Nautilus Biotechnology Reports First Quarter 2022 Financial Results

GlobeNewswire May 3, 2022

Nautilus Biotechnology Appoints Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development

GlobeNewswire April 12, 2022

Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022

GlobeNewswire April 7, 2022

Nautilus Biotechnology to Present at EuPA and AACR Meetings

GlobeNewswire April 4, 2022

Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors

GlobeNewswire March 31, 2022

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results

GlobeNewswire February 24, 2022

Nautilus to Participate in the 42nd Annual Cowen Health Care Conference

GlobeNewswire February 16, 2022

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

GlobeNewswire January 27, 2022

Nautilus and Abcam Announce Strategic Partnership to Accelerate Exploration of the Proteome

GlobeNewswire November 2, 2021

Nautilus Biotechnology Reports Third Quarter 2021 Financial Results

GlobeNewswire November 2, 2021

Nautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021

GlobeNewswire October 11, 2021

Nautilus to Participate in the Morgan Stanley Global Healthcare Conference

GlobeNewswire September 3, 2021

Nautilus Biotechnology Reports Second Quarter 2021 Financial Results

GlobeNewswire August 10, 2021

Nautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development

GlobeNewswire August 9, 2021

Nautilus Biotechnology to Announce Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021

GlobeNewswire July 13, 2021

Nautilus Biotechnology Appoints Emma Lundberg, Ph.D., to Scientific Advisory Board

GlobeNewswire June 17, 2021

Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome

GlobeNewswire June 9, 2021